Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Lurasidone in Bipolar I Disorder
jRCT2080222270Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2013
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in bipolar I disorder, sponsored by Sumitomo Pharma. Primary endpoints: Long-term effectiveness of lurasidone and Long-term safety and tolerability of lurasidone. Started Oct 2013; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on jRCT2080222270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222270.